Inhibikase Therapeutics, Inc.
Chris Meyer has a diverse work experience, starting with their current role as the Vice President of Clinical Operations at Inhibikase Therapeutics, Inc. Chris previously held the position of Vice President Operations at Axial Therapeutics, Inc., where they managed program management and clinical operations. Before that, they worked at Momenta Pharmaceuticals as the Director of Program and Alliance Leadership, overseeing program management of commercial products. Chris also worked at OvaScience as the Director of Program and Alliance Management, responsible for implementing commercial growth strategies. Prior to that, they held various roles at Lonza, including Global Director of Contract Management and Head of Program Management for a manufacturing facility. Earlier in their career, they served as the New England Regional Manager and Sr. Engineering and Business Development Lead at Hyde Engineering + Consulting, and as a Process Engineer at Alkermes, Inc.
Chris Meyer has a Master of Business Administration (MBA) degree in International Business from the D'Amore-McKim School of Business at Northeastern University. Prior to that, they obtained a Bachelor of Science (BS) degree in Mechanical Engineering with a minor in BioMechanics from Worcester Polytechnic Institute. Additionally, they have obtained a Project Management Professional (PMP) certification from the Project Management Institute, which was obtained in the year 2023 (month unspecified).
This person is not in any teams
This person is not in any offices
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.